Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(/p Myslee(R) 85 -11.5% ...),Health

Myslee(R) 85 -11.5% 1,093 -35.0% 72 -20.0%

Copaxone(R) 324 +16.1% 801 +19.4% 52 -5.5%

Aprovel(R) 838 +3.8% - - 242 +21.0%

Tritace(R) 466 -8.8% 1 -92.9% 274 -37.4%

Allegra(R) 54 +3.8% 369 +4.8% 283 +21.5%

Amaryl(R) 116 -33.7% 9 -35.7% 267 +9.4%

Actonel(R) 204 -16.0% - - 116 +10.5%

Depakine(R) 216 +2.4% - - 100 +13.6%

Xatral(R) 167 -20.5% 107 +25.9% 59 +22.9%

Nasacort(R) 44 +10.0% 222 +13.3% 28 +3.7%

Comments by product

Net sales of Lovenox(R), the leading low molecular weight heparin on the market, rose by 17.4% in the quarter to euro 674 million. The product reported strong growth across all three regions: 16.5% in the United States, 15.5% in Europe, and 27.9% in the "Other Countries" region. In the United States, increased use in medical prophylaxis remains the main growth driver.

In January 2008, Lovenox(R) was approved in Japan for the prevention of venous thromboembolism (VTE) in patients undergoing orthopedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery. Further clinical trials are ongoing to extend the product's indication in Japan to patients undergoing abdominal surgery who are at risk of venous thromboembolism.

Lantus(R) is the first insulin brand in the world to exceed euro 2 billion of sales (euro 2,031 million). In the fourth quarter, the product enjoyed strong growth across all three regions. The new SoloSTAR(R) disposable pen used to administer Lantus(R) is now available in most European countries and in the United States.

Findings presented at the American Heart Association's 2007 Scient
'/>"/>